WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced its partner Betta Pharmaceuticals has dosed the first patient in the...Read more
TNG462 demonstrated durable clinical activity across multiple tumor types, including non-small cell lung cancer (NSCLC) and pancreatic cancer, in ongoing phase 1/2 clinical trial, moving into full development Multiple TNG462 combination studies planned in 1H 2025 Clinical...Read more
Preclinical data for LNCB74 highlights its potential as therapeutic for treating multiple solid tumor indications; Investigational New Drug (IND) application filing expected by year-end Additional biomarker data support proposed mechanism of action of NC410 BELTSVILLE, Md., Nov....Read more
NASHVILLE, Tenn., Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban...Read more
This represents the fourth indication granted a Breakthrough Device Designation for the SCD by FDA DENVER, Nov. 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the...Read more
Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the...Read more
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Medpace | 30.03 9.15 | $358.27 |
| UnitedHealth | 29.66 5.23 | $596.69 |
| Humana | 27.91 10.71 | $288.51 |
| Charles River Laboratories | 25.52 13.53 | $214.20 |
| McKesson | 24.03 4.57 | $549.31 |
| ZIVO Bioscience | 18.40 1,672.73 | $19.50 |
| Chemed | 16.82 3.15 | $549.99 |
| Masimo | 16.07 10.60 | $167.63 |
| United Therapeutics | 14.72 3.85 | $397.49 |
| U.S. Physical Therapy | 14.57 17.65 | $97.10 |
| Glaukos | 12.78 10.00 | $140.64 |
| Inspire Medical Systems | 12.63 6.35 | $211.63 |
| Tempus AI | 12.47 28.02 | $56.97 |
| Mettler-Toledo | 12.40 0.89 | $1,398.19 |
| Elevance Health | 11.16 2.67 | $428.93 |
| Belite Bio | 10.98 15.66 | $81.08 |
| Finch Therapeutics | 10.20 566.67 | $12.00 |
| National HealthCare | 9.41 7.78 | $130.34 |
| Company | Volume | Last Trade |
|---|---|---|
| Pfizer | 56,429,480 | $27.36 |
| Cardio Diagnostics | 50,741,539 | $0.36 |
| LifeWallet | 39,193,614 | $0.12 |
| Vyome | 36,361,564 | $0.22 |
| CVS Health | 26,184,508 | $61.61 |
| Sonnet BioTherapeutics | 24,847,803 | $3.73 |
| Walgreens Boots Alliance | 21,158,442 | $9.23 |
| Bluejay Diagnostics | 19,907,928 | $0.09 |
| Teva Pharmaceutical | 17,559,156 | $17.43 |
| Bionomics | 17,050,060 | $0.28 |
| Exact Sciences | 16,560,836 | $54.72 |
| AstraZeneca | 15,014,215 | $63.85 |
| Tango Therapeutics | 14,843,017 | $3.24 |
| PacBio | 14,468,905 | $2.65 |
| Clover Health | 14,247,400 | $4.35 |
| GSK | 13,860,483 | $35.90 |
| Oscar Health | 12,128,938 | $15.55 |
| Shineco | 12,127,008 | $0.15 |
| Sangamo Therapeutics | 11,934,285 | $2.47 |
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
